For years, Sara worked in a hospital, making care possible for others. Now, after being diagnosed with breast cancer, she was the one in need of care.
As the pandemic clearly revealed, there is an urgent need for a more cohesive, coordinated approach to streamline global regulatory guidelines to ensure patients have faster access to new and innovative drugs. Coincidentally, the height of the global pandemic coincided with the start of a new chapter in my career journey, one that would allow me to support our clients in the implementation of new requirements for the Eurasian Economic Union (EAEU), an economic union of countries in Eastern European, Central and Western Asia.
These new requirements allow for the five member states to operate a national medicines market in a single space, and to apply for registration of medicines and their release in all five markets simultaneously under common procedures and reduced administrative costs.
Coming to Parexel at this critical juncture has provided me the opportunity to assist our clients in navigating the new guidelines for those who are seeking to enter the EAEU market, where I have spent the past two years supporting customers in Russia, Ukraine and Belarus with dossier compilation and submission.
Defining the Need: EAEU History
The EAEU was established to encourage the free movement of goods and services as well as the potential for creating a single currency in the future. In May of 2017, three years after the EAEU treaty was signed, the EAEU countries ratified the regulatory framework for a common market for medicines, creating a set of 26 documents to be gradually implemented across all countries and fully adopted by 2025. The guidelines are based the following principles and are designed to loosely align with EU guidelines:
Establishing a Consistent EAEU and EU framework
The more consistent the global standards, the more expedient the approval of new medications within larger geographic regions.
In 2017, the Ministry of Technical Regulation of the EAEU and the leadership of European Directorate for the Quality of Medicines (EDQM) convened to discuss the creation of a unified pharmacopeia in EAEU and EU countries. In early 2019, a unified electronic drug labelling guideline was introduced to allow for tracking and greater transparency into the origin of a particular batch of medicine or medical device to further optimize quality and enhance safety for patients.
The common set of guidelines is designed to reduce the complexity and administrative burden on the pharmaceutical industry; to expand member countries’ access to new products; to enhance product quality; and to reduce administrative costs and prices for essential medicines for patients.
Implementing this regulation has required significant time and resources among member states, in particular the Russian Federation, as there are considerable differences between the respective regulations of each member nation.
Moreover, there are set timelines for abiding by the new regulations that will influence market access and product marketing going forward. On Dec. 31 of 2020, the national requirements for submission process will be replaced by Decentralized Procedure (DCP)/ Mutual Recognition Procedure (MRP).
In order to remain on the EAEU market, it is mandatory that all the medicinal products authorized prior to this date follow the harmonization process for the EAEU regulation until December 31, 2025.
EAEU Initial Implementation Requirements
The advantages of Electronic Common Technical Documents (eCTD) are well established, including greater efficiency and shorter timelines for dossier analysis. However, eCTD adoption been slower in some parts of the world than others, including in the EAEU, where submission of medicines dossiers continues to be done by paper and CD. Recently, Russian-speaking countries have begun to align their manufacturing sites with international standards, including approving international pharmacopeias using E.U. and U.S. guidelines as their standard. The move to eCTD is critical for manufacturers who want to be competitive in this global market.
Preparing for EAEU Electronic submission
Among the new EAEU requirements is to provide the electronic dossier in a particular format of the XML (R.022, instead of the known format R.017). This second XML version contains information on the documents submitted, together with specific identifiers for each document type. To help customers adapt to these new standards, Parexel is working closely to provide detailed guidance, including:
Support and Consultation
Parexel’s regulatory submissions and publishing team has extensive global experience in EAEU countries to ensure that submissions are streamlined and as consistent as possible across the globe. We provide:
Global Regulatory Alignment Expands Global Patient Access
As patient demand for new drugs continues to rise, health authorities in each region of the world are recognizing the need to align their respective practices and procedures to ensure their residents have rapid access to the latest therapies. Toward this end, health agencies in some emerging markets are now open to and accepting other regions’ approvals, recognizing that the rigorous review process in the U.S. and Europe, for example, are sufficient for approval in their own countries. As one example, sponsors can now make parallel applications to the FDA and EMA for orphan drug designation via a single common form. As the EAEU continues to adapt its guidelines to expedite the drug development process, sponsors will increasingly view this region as an attractive market for pursuing clinical research opportunities.
Lessons from China and the United States on the use of RWE in regulatory submissions
Jul 19, 2021
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Six top tips to prepare for the new EU Clinical Trial Regulation
Apr 13, 2021
Assessing the need for comparative clinical trials in biosimilar development programs
Sep 21, 2023
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Part 2: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
Part 3: Risk-based Quality Management Video (RBQM) Series
Nov 11, 2021
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Biosimilar Development: Are therapeutic clinical trials needed?
Nov 16, 2021
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021